Kansas City’s Mid-America Heart Institute Leads Global Phase III Trial Investigating Farxiga in COVID-19 Patients

Dr. Mikhail Kosiborod with Saint Luke’s Mid-America Heart Institute is leading a clinical trial investing the use of a diabetic drug called dapagliflozin. Apparently, a new study commenced to look the drug as a means of protecting vital organs from damage caused by...

Pin It on Pinterest